Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc. has demonstrated solid revenue growth within its Retail segment, reporting $255 million in sales for the quarter, which reflects an 8.1% quarter-over-quarter and a 7.8% year-over-year increase. The company is on track to achieve an expected free cash flow (FCF) of $205 million in 2025, significantly increasing from $109 million in 2024, as it has maintained positive FCF for four consecutive quarters. Furthermore, the gross and operating margins are expected to improve moderately, with targeted annual expansions of 25-50 basis points and 50-100 basis points, respectively, indicating a potential enhancement in overall profitability in the coming years.

Bears say

Diebold Nixdorf's stock outlook is negative due to several fundamental factors affecting its financial health, including technological missteps and an inability to innovate, which may hinder revenue growth and profitability. The company's Banking segment has experienced a decline in total gross margins, which were reported at 26.8%, reflecting a 70 basis point decrease quarter-over-quarter, indicating increasing competitive pressure and potential issues in demand for its products. Additionally, uncertainties such as tariff-related costs, supply chain disruptions, and volatility in foreign exchange rates further complicate the company's ability to maintain stable financial performance and meet its debt obligations.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.